Have you taken an antibiotic such as Cipro (ciprofloxacin), Levaquin (levofloxacin), or Avelox (moxifloxacin)? Would you be willing to help in a survey-based medical research study?
Dr. Beatrice A. Golomb and her colleagues at the University of California, San Diego are conducting a 
new study to identify and describe side effects and risk factors for good and bad outcomes involving antibiotics in the fluoroquinolone class. Other example fluoroquinolones include Zymar (gatifloxacin), Floxin (ofloxacin), Zagam (sparfloxacin), Trovan (trovafloxacin), Tavanic, and Vigamox.
Whether you believe you have experienced side effects or you believe you have tolerated them, you are invited to participate in this voluntary study. Participants possessing English language fluency from all countries are accepted.
Study participants will be asked to complete questionnaire(s). By participating in these surveys, you can help us further understand the effects of fluoroquinolones and report findings to the medical community (including prescribing physicians) and the general public. Surveys will cover your overall health, well-being, fluoroquinolones taken, and symptoms; impacts on your life and career; and your personal story.
For those without side effects, there is currently just one survey taking 20-30 minutes to complete.
For those having adverse effects, there are currently 3 (voluntary) questionnaires that can be done separately, each taking approximately 40-90 minutes (time varies per individual). Each survey addresses a different set of concerns related to fluoroquinolone effects. More voluntary surveys may be available in the future. Compensation for taking the surveys is not available.
If there is a chance you are interested in participating, please visit our website at:
for further information on this important study.
If you know of anyone else who might consider participating, then please pass on our website address. We truly appreciate your participation and referrals.
-The UCSD Fluoroquinolone Effects Study
UCSD Human Research Protections Program has approved the above advertisement wording.
Leave A Comment